302 related articles for article (PubMed ID: 34773467)
21. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S
Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990
[TBL] [Abstract][Full Text] [Related]
22. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
[TBL] [Abstract][Full Text] [Related]
23. Based on Gadolinium Ethoxybenzyl DTPA-Enhanced MRI: Diagnostic Performance of the Category-Modified LR-5 Criteria in Patients At Risk for Hepatocellular Carcinoma.
Li S; Deng K; Qiu J; Wang P; Yin D; Xie Y; Yu Y
Technol Cancer Res Treat; 2024; 23():15330338241256859. PubMed ID: 38780516
[No Abstract] [Full Text] [Related]
24. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
25. Long-term evolution of LR-2, LR-3 and LR-4 observations in HBV-related cirrhosis based on LI-RADS v2018 using gadoxetic acid-enhanced MRI.
Xing F; Zhang T; Miao X; Lu J; Du S; Jiang J; Xing W
Abdom Radiol (NY); 2023 Dec; 48(12):3703-3713. PubMed ID: 37740759
[TBL] [Abstract][Full Text] [Related]
26. Added value of enhanced CT on LR-3 and LR-4 observation of Gd-EOB-DTPA MRI for the diagnosis of HCC: are CT and MR washout features interchangeable?
Lim K; Kwon H; Cho J; Kim D; Kang E; Kim S
Br J Radiol; 2022 Apr; 95(1132):20210738. PubMed ID: 34928175
[TBL] [Abstract][Full Text] [Related]
27. Threshold growth has a limited role in differentiating hepatocellular carcinoma from other focal hepatic lesions.
Lyu R; Wang D; Hu W; Gao Z; Yu C; Wang J; Li M; Jia K
BMC Med Imaging; 2023 Dec; 23(1):201. PubMed ID: 38049717
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
29. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Diagnostic performance of category-adjusted LR-5 using modified criteria.
Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
PLoS One; 2020; 15(11):e0242344. PubMed ID: 33186378
[TBL] [Abstract][Full Text] [Related]
30. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
[TBL] [Abstract][Full Text] [Related]
31. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
[No Abstract] [Full Text] [Related]
33. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
[TBL] [Abstract][Full Text] [Related]
34. Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI.
Kwag M; Choi SH; Choi SJ; Byun JH; Won HJ; Shin YM
Radiology; 2022 Dec; 305(3):614-622. PubMed ID: 35972362
[TBL] [Abstract][Full Text] [Related]
35. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
Ghadimi M; Birnbaum J; Kamel IR; Sirlin CB; Chernyak V
Eur Radiol; 2022 May; 32(5):3327-3333. PubMed ID: 34807269
[TBL] [Abstract][Full Text] [Related]
36. Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging.
Kang JH; Choi SH; Byun JH; Kim DH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
Eur Radiol; 2020 May; 30(5):2881-2889. PubMed ID: 32020399
[TBL] [Abstract][Full Text] [Related]
37. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
[TBL] [Abstract][Full Text] [Related]
38. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI.
Kang HJ; Lee JM; Jeon SK; Jang S; Park S; Joo I; Yoon JH; Han JK
Eur Radiol; 2021 Feb; 31(2):824-833. PubMed ID: 32845387
[TBL] [Abstract][Full Text] [Related]
39. Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS.
Hwang SH; Park S; Han K; Choi JY; Park YN; Park MS
Abdom Radiol (NY); 2019 Sep; 44(9):3078-3088. PubMed ID: 31165907
[TBL] [Abstract][Full Text] [Related]
40. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
